Humacyte, Inc. Announces Proposed Public Offering of Common Stock
Key Highlights for Investors
-
Public Offering Launched:
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company, has announced the commencement of an underwritten public offering of its common stock. -
Offering Details:
The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering. All shares are to be offered by Humacyte. -
Book-Running Managers:
Barclays, BTIG, and Titan Partners (a division of American Capital Partners) are acting as joint book-running managers for the offering. -
Use of Proceeds:
Proceeds from this offering are expected to fund:- Commercialization of Symvess®, the company’s first FDA-approved product.
- Planned filing of a Biologics License Application (BLA) supplement for a hemodialysis indication and related activities.
- Development of additional pipeline product candidates.
- Working capital and general corporate purposes.
-
SEC Filing:
The offering will be made pursuant to an effective shelf registration statement on Form S-3, with related prospectus supplements available on the SEC’s website.
Important Information for Shareholders
-
Potential Share Dilution:
The proposed public offering will result in the issuance of additional shares, which could lead to dilution for current shareholders. -
Market Conditions Apply:
The completion, timing, size, and terms of the offering are subject to market conditions and may not be guaranteed. -
Commercial Progress:
Humacyte launched its first FDA-approved product, Symvess, in the U.S. in Q1 2025, positioning the company as a commercial-stage player in bioengineered human tissues. -
Regulatory Status:
Aside from the FDA approval for extremity vascular trauma, Humacyte’s Acellular Tissue Engineered Vessel (ATEV) remains investigational and is not yet approved for other indications. -
Forward-Looking Statements and Risks:
The company cautions that forward-looking statements are subject to significant risks, uncertainties, and changes in regulatory or market conditions. There is no guarantee that the offering will be completed or that capital will be raised as intended.
Details for Interested Investors
Copies of the preliminary prospectus supplement and accompanying prospectus, when available, can be obtained from:
- Barclays Capital Inc.: [email protected] or (888) 603-5847
- BTIG, LLC: [email protected] or (212) 593-7555
- Titan Partners Group LLC: [email protected] or (929) 833-1246
About Humacyte
Humacyte, Inc. is pioneering the development and commercialization of universally implantable, off-the-shelf, bioengineered human tissues, advanced tissue constructs, and organ systems. Their scalable technology platform aims to improve patient outcomes across multiple therapeutic areas by creating proprietary, acellular human tissues. The company’s flagship product, Symvess, was commercially launched in the U.S. in Q1 2025.
For uses other than FDA-approved extremity vascular trauma indication, Humacyte’s ATEV remains investigational and is not approved for sale by the FDA or other regulatory agencies.
Key Risks and Forward-Looking Statements
Humacyte emphasizes that forward-looking statements—such as expectations regarding the timing and success of the proposed offering, the ability to raise capital, and the use of proceeds—are subject to significant risks and uncertainties. Actual results may differ materially due to changes in laws, regulations, business conditions, and other risk factors outlined in Humacyte’s public SEC filings.
- Investors are urged to review the “Risk Factors” section in the company’s Annual Report (Form 10-K for the year ended December 31, 2025) and Quarterly Report (Form 10-Q for the quarter ended March 31, 2026).
- Most risks are outside Humacyte’s control and may impact future performance and share value.
Contact Information
Investor Contact:
Joyce Allaire, LifeSci Advisors LLC
+1-617-435-6602
[email protected]
[email protected]
Media Contact:
Rich Luchette, Precision Strategies
+1-202-845-3924
[email protected]
[email protected]
Disclaimer: This article is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. The completion and outcome of the offering are subject to market conditions and various risks. Investors should consult the company’s official filings and seek professional advice before making investment decisions. The information herein is based on publicly available statements as of the press release date and may not reflect subsequent developments.
